Melatonin in the physiology and pathology of transparent structures and media of the eye (cornea, lens, and intraocular fluid)

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The organ of vision is the most important means of understanding the external world. Up to 90% of all afferent information enters the brain through this analyzer. The eye, along with other sensory organs, functions as a device for perceiving signals that are subsequently transmitted to the brain. The visual system consists of a peripheral component — the eyeball with its light-perceiving apparatus, the optic nerve, and central components — the lateral geniculate body and the visual cortex. Naturally, the normal functioning of the components of this system ensures a number of biologically important effects, adequate perception of the environment, and a high quality of life. The condition of the transparent structures and media of the eye (cornea, lens, and intraocular fluid) is of great importance for the functioning of the visual apparatus, since the light stream is conducted through them to the retina. These structures are primarily exposed to adverse environmental factors (toxic agents, ultraviolet radiation, etc.), which results in the development of pathological conditions that cause disturbances in light conduction. Both surgical and conservative treatment methods are used to correct them, but these methods are not always successful. The indole compound melatonin has recently been considered one of the alternative and effective treatments for ophthalmic pathology and has been attracting the attention of specialists in various fields of medicine for more than 60 years since its discovery. This is because melatonin has a wide range of valuable pharmacological properties, including anti-inflammatory, antioxidant, and immunotropic effects, as well as the ability to influence the functioning of the cardiovascular system, the gastrointestinal tract, and exert a number of other effects. Melatonin is produced in the pineal gland and enters peripheral tissues via the bloodstream, where it exerts its properties. However, indole synthesis also occurs in peripheral tissues, where this extraepiphyseal melatonin exhibits its effects. Melatonin is intensively synthesized in various structures of the eye, especially in the retina, where a full set of enzymes is present for the synthesis of indole and for specific melatonin receptors. Such information has led to the use of melatonin in the treatment of various ophthalmic pathologies.

Full Text

Restricted Access

About the authors

Karen B. Ovanesov

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: ovanesov2007@mail.ru
ORCID iD: 0000-0001-7325-8027
SPIN-code: 1598-9971

MD, Dr. Sci. (Medicine)

Russian Federation, Saint Petersburg

Ruslan I. Glushakov

Institute of Experimental Medicine; Saint Petersburg State Pediatric Medical University

Email: glushakoffruslan@yandex.ru
ORCID iD: 0000-0002-0161-5977
SPIN-code: 6860-8990

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Saint Petersburg; Saint Petersburg

Artur R. Badakshanov

North-Western State Medical University named after I.I. Mechnikov

Email: mepharm@yandex.ru
ORCID iD: 0009-0005-3776-3735
SPIN-code: 7529-2400

Cand. Sci. (Pharmacy)

Russian Federation, Saint Petersburg

Matvey N. Dergilev

North-Western State Medical University named after I.I. Mechnikov

Email: Lokkup34@gmail.com
ORCID iD: 0009-0006-7524-3578
SPIN-code: 3105-4787
Russian Federation, Saint Petersburg

Aleksandr A. Bartosh-Zeleny

Almazov National Medical Research Center

Email: alexbartoshz@mail.ru
ORCID iD: 0000-0002-4284-3562
SPIN-code: 4402-4144
Russian Federation, Saint Petersburg

Daredzhan B. Tsurtsumiya

North-Western State Medical University named after I.I. Mechnikov

Email: dasha.tsurtsumiya@mail.ru
ORCID iD: 0000-0001-7806-9364
SPIN-code: 9480-2672

Cand. Sci. (Medicine)

Russian Federation, Saint Petersburg

References

  1. Arushanyan EB, Beyer EV. Melatonin: biology, pharmacology, clinic. Stavropol: Stavropol State Medical University; 2015. 393 p. ISBN: 978-5-89822-400-4 EDN: UPCJIZ
  2. Arushanyan EB, Ovanesov KB. The significance of melatonin for physiology and pathology of the eye. Medical Bulletin of the North Caucasus. 2016;11(1):126–133. doi: 10.14300/mnnc.2016.11017 EDN: VVXSZV
  3. Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: Location, second messengers and role in ocular physiology. Pharmacol Ther. 2007;113(3):507–522. doi: 10.1016/j.pharmthera.2006.11.003 EDN: MBRYHX
  4. Ovanesov KB. Significance of the retinalpineal system for psychopharmacological effects [dissertation]. Moscow; 2004. 215 p. Available from: EDN: NPXDXR
  5. Charlton-Perkins M, Cook TA. Building a fly eye: terminal differentiation events of the retina, corneal lens, and pigmental epithelia. Curr Top Dev Biol. 2010;93:129–173. doi: 10.1016/B978-0-12-385044-7.00005-9
  6. Rada JAS, Wiechmann AF. Melatonin receptors in chick ocular tissues: implications for a role of melatonin in ocular growth regulation. Invest Ophthalmol Vis Sci. 2006;47(1):25–33. doi: 10.1167/iovs.05-0195
  7. Wahl C, Li T, Takagi Y, Howland H. The effects of light regimes and hormones on corneal growth in vivo and in organ culture. J Anat. 2011;219(6):766–775. doi: 10.1111/j.1469-7580.2011.01429.x
  8. Wiechmann AF, Rada JA. Melatonin receptor expression in the cornea and sclera. Exp Eye Res. 2003;77(2):219–225. doi: 10.1016/s0014-4835(03)00126-x
  9. Wiechmann AF, Summers JA. Circadian rhythms in the eye: The physiological significance of melatonin receptors in ocular tissues. Prog Retin Eye Res. 2008;27(2):137–160. doi: 10.1016/j.preteyeres.2007.10.001
  10. Wiechmann AF, Hollaway LR, Rada JA. Melatonin receptor expression in Xenopus laevis surface corneal epithelium: diurnal rhythm of lateral membrane localization. Mol Vis. 2009;15:2384–2403.
  11. Baba K, Davidson AJ, Tosini G. Melatonin entrains PER2:: LUC bioluminescence circadian rhythm in the mouse cornea. Invest Ophthalmol Vis Sci. 2015;56(8):4753. doi: 10.1167/iovs.15-17124
  12. Huynh AV, Buhr ED. Melatonin adjusts the phase of mouse circadian clocks in the cornea both ex vivo and in vivo. J Biol Rhythms. 2021;36(5): 470–482. doi: 10.1177/07487304211032385 EDN: OFTVPT
  13. Crooke A, Huete-Toral F, Martínez-Águila A, et al. Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential. Expert Opin Drug Discov. 2012;7(10):989–1001. doi: 10.1517/17460441.2012.714769
  14. Lassen N, Black WJ, Estey T. The role of corneal crystalline in the cellular defense mechanisms against oxidative stress. Semin Cell Dev Biol. 2008;19(2):100–112. doi: 10.1016/j.semcdb.2007.10.004 EDN: XVLBPI
  15. Jin R, Li Y, Jin H, et al. Melatonin type 2 receptor activation regulates blue light exposure-induced mouse corneal epithelial damage by modulating impaired autophagy and apoptosis. Int J Mol Sci. 2022;23(19):11341. doi: 10.3390/ijms231911341 EDN: MIWFQF
  16. Ciuffi M, Pisanello M, Pagliai G, et al. Antioxidant protection in cultured corneal cells and whole corneas submitted to UV-B exposure. J Photochem Photobiol B. 2003;71(1–3):59–68. doi: 10.1016/j.jphotobiol.2003.07.004 EDN: ERVRNZ
  17. Wang B, Zuo X, Peng L, et al. Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye. Exp Eye Res. 2021;205:108491. doi: 10.1016/j.exer.2021.108491 EDN: RYTYTL
  18. Lou Q, Pan L, Xiang S, et al. Suppression of NLRP3/Caspase-1/GSDMD mediated corneal epithelium pyroptosis using melatonin-loaded liposomes to inhibit benzalkonium chloride-induced dry eye disease. Int J Nanomedicine. 2023;18:2447–2463. doi: 10.2147/ijn.s403337 EDN: CDUGSC
  19. Choi SI, Dadakhujaev S, Ryu H, et al. Melatonin protects against oxidative stress in granular corneal dystrophy type 2 corneal fibroblasts by mechanisms that involve membrane melatonin receptors. J Pineal Res. 2011;51(1):94–103. doi: 10.1111/j.1600-079x.2011.00866.x
  20. Frost LS, Mitchell CH, Boesze-Battaglia K. Autophagy in the eye: Implications for ocular cell health. Exp Eye Res. 2014;124:56–66. doi: 10.1016/j.exer.2014.04.010 EDN: SPXYMR
  21. Choi S, Lee E, Akuzum B, et al. Melatonin reduces endoplasmic reticulum stress and corneal dystrophy-associated TGFBIp through activation of endoplasmic reticulum-associated protein degradation. J Pineal Res. 2017;63(3):e12426. doi: 10.1111/jpi.12426 EDN: YIPULV
  22. Ahn JH, Kim HD, Sharif-Md Abuzar, et al. Intracorneal melatonin delivery using 2-hydroxypropyl-β-cyclodextrin ophthalmic solution for granular corneal dystrophy type 2. Int J Pharm. 2017;529(1–2):608–616. doi: 10.1016/j.ijpharm.2017.07.016
  23. Matuwana D, Hong E, Huang S, et al. Near-infrared activated liposomes for neuroprotection in glaucoma. J Mater Chem B. 2024. doi: 10.1039/d4tb00745j EDN: OIMDJH
  24. Altug B, Soykan MN, Eyubova S, et al. Crosstalk among miR-29, α-SMA, and TGFβ1/β3 in melatonin-induced exosome (Mel-prExo) treated human limbal mesenchymal stem cells (hLMSCs): An insight into scarless healing of the cornea. BioFactors. 2024;50(6):1287–1297. doi: 10.1002/biof.2085
  25. Bonilla-Vidal L, Espina M, García ML, et al. Combination of apigenin and melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment. Int J Pharm. 2025;670:125160. doi: 10.1016/j.ijpharm.2024.125160 EDN: QQILTN
  26. Bessone CDV, Martinez SM, Luna JD, et al. Neuroprotective effect of melatonin loaded in ethylcellulose nanoparticles applied topically in a retinal degeneration model in rabbits. Exp Eye Res. 2020;200:108222. doi: 10.1016/j.exer.2020.108222 EDN: LIUCNT
  27. Konuk ŞG, Özdemir S, Kılıç R, et al. Exploring the therapeutic potential: sinomenine and melatonin in alkali-induced corneal burns. Int Ophthalmol. 2024;44(1):422. doi: 10.1007/s10792-024-03327-y
  28. Meng J, Lin B, Huang S, et al. Melatonin exerts anti-angiogenic and anti-inflammatory effects in alkali-burned corneas. Ann Transl Med. 2022;10(8):432. doi: 10.21037/atm-21-4927 EDN: MBWYAS
  29. Crooke A, Guzman-Aranguez A, Mediero A, et al. Effect of melatonin and analogues on corneal wound healing: involvement of Mt2 melatonin receptor. Curr Eye Res. 2015;40(1):56–65. doi: 10.3109/02713683.2014.914540
  30. Polat OA, Karabulut D, Akkul Z, et al. Evaluation of histologic, antiapoptotic and antioxidant effects of melatonin against the acute ocular toxicity of Cisplatin. Tissue Cell. 2023;85:102226. doi: 10.1016/j.tice.2023.102226 EDN: XZJSPI
  31. An S, Anwar K, Ashraf M, et al. Chlorine-induced toxicity on murine cornea: exploring the potential therapeutic role of antioxidants. Cells. 2024;13(5):458. doi: 10.3390/cells13050458 EDN: KZHLCR
  32. Zhu Z, Peng R, Shen H, et al. Treatment with melatonin after corneal graft attenuates rejection. Front Pharmacol. 2021;12:778892. doi: 10.3389/fphar.2021.778892 EDN: JHVIIT
  33. Yoon HJ, Jiang E, Liu J, et al. A Selective Melatonin 2 receptor agonist, IIK7, relieves blue light-induced corneal damage by modulating the process of autophagy and apoptosis. Int J Mol Sci. 2024;25(20):11243. doi: 10.3390/ijms252011243 EDN: ZIFMRZ
  34. Navarro Gil FJ, Huete-Toral F, Crooke A, et al. Effect of melatonin and its analogs on tear secretion. J Pharmacol Exp Ther. 2019;371(1):186–190. doi: 10.1124/jpet.119.259192
  35. Navarro-Gil FJ, Huete-Toral F, Domínguez-Godínez CO, et al. Contact lenses loaded with melatonin analogs: a promising therapeutic tool against dry eye disease. J Clin Med. 2022;11(12):3483. doi: 10.3390/jcm11123483 EDN: LKAUTG
  36. Nemr AA, El-Mahrouk GM, Badie HA. Enhancement of ocular anti-glaucomic activity of agomelatine through fabrication of hyaluronic acid modified-elastosomes: formulation, statistical optimisation, in vitro characterisation, histopathological study, and in vivo assessment. J Microencapsul. 2023;40(6):423–441. doi: 10.1080/02652048.2023.2215326 EDN: IQBPLC
  37. Itoh MT, Takahashi N, Abe M, Shimizu K. Expression and cellular localization of melatonin-synthesizing enzymes in the rat lens. J Pineal Res. 2007;42(1):92–96. doi: 10.1111/j.1600-079x.2006.00389.x EDN: MIYTVF
  38. Abe M, Itoh MT, Miyata M, et al. Detection of melatonin, its precursors and related enzyme activities in rabbit lens. Exp Eye Res. 1999;68(2): 255–262. doi: 10.1006/exer.1998.0601
  39. Abe M, Itoh MT, Miyata M, et al. Circadian rhythm of serotonin N-acetyltransferase activity in rat lens. Exp Eye Res. 2000;70(6):805-808. doi: 10.1006/exer.2000.0845
  40. Nourazaran M, Yousefi R, Moosavi-Movahedi F, et al. The structural and functional consequences of melatonin and serotonin on human αB-crystallin and their dual role in the eye lens transparency. Biochim Biophys Acta Proteins Proteom. 2023;1871(5):140928. doi: 10.1016/j.bbapap.2023.140928 EDN: JTBIQZ
  41. Ostrin LA. Ocular and systemic melatonin and the influence of light exposure. Clin Exp Optom. 2019;102(2):99–108. doi: 10.1111/cxo.12824 EDN: HUTQAS
  42. Wiechmann AF, Udin SB, Summers Rada JA. Localization of Mel1b melatonin receptor-like immunoreactivity in ocular tissues of Xenopus laevis. Exp Eye Res. 2004;79(4):585–594. doi: 10.1016/j.exer.2004.07.004
  43. Quay WB. Increases in volume, fluid content, and lens weight of eyes following systemic administration of melatonin. J Pineal Res. 1984;1(1):3–13. doi: 10.1111/j.1600-079x.1984.tb00190.x
  44. Scuderi L, Davinelli S, Iodice CM, et al. Melatonin: implications for ocular disease and therapeutic potential. Curr Pharm Des. 2019;25(39):4185–4197. doi: 10.2174/1381612825666191113110225
  45. Crooke A, Huete-Toral F, Colligris B, Pintor J. The role and therapeutic potential of melatonin in age-related ocular diseases. J Pineal Res. 2017;63(2):e12430. doi: 10.1111/jpi.12430 EDN: YGQLDH
  46. Hung CH, Huang JY, Hung YC, et al. Association between melatonin use and cataract risk: a target trial emulation retrospective cohort study. Antioxidants. 2025;14(8):1016. doi: 10.3390/antiox14081016 EDN: PIZTNZ
  47. Bai J, Dong L, Song Z, et al. The role of melatonin as an antioxidant in human lens epithelial cells. Free Radic Res. 2013;47(8):635–642. doi: 10.3109/10715762.2013.808743
  48. Lledó VE, Alkozi HA, Sánchez-Naves J, et al. Melatonin counteracts oxidative damage in lens by regulation of Nrf2 and NLRP3 inflammasome activity. Exp Eye Res. 2022;215:108912. doi: 10.1016/j.exer.2021.108912 EDN: ZPDDAU
  49. Mi Y, Wei C, Sun L, et al. Melatonin inhibits ferroptosis and delays age-related cataract by regulating SIRT6/p-Nrf2/GPX4 and SIRT6/NCOA4/FTH1 pathways. Biomed Pharmacother. 2023;157:114048. doi: 10.1016/j.biopha.2022.114048 EDN: DSGIOT
  50. Yağci R, Aydin B, Erdurmuş M, et al. Use of melatonin to prevent selenite-induced cataract formation in rat eyes. Curr Eye Res. 2006;31(10): 845–850. doi: 10.1080/02713680600899663
  51. Lledó VE, Alkozi HA, Sánchez-Naves J, et al. Modulation of aqueous humor melatonin levels by yellow-filter and its protective effect on lens. J Photochem Photobiol B. 2021;221:112248. doi: 10.1016/j.jphotobiol.2021.112248 EDN: ZRTMCN
  52. Khorsand M, Akmali M, Akhzari M. Efficacy of melatonin in restoring the antioxidant status in the lens of diabetic rats induced by streptozotocin. J Diabetes Metab Disord. 2019;18(2):543–549. doi: 10.1007/s40200-019-00445-8 EDN: HZXXUX
  53. Khorsand M, Akmali M, Sharzad S, Beheshtitabar M. Melatonin reduces cataract formation and aldose reductase activity in lenses of streptozotocin-induced diabetic rat. Iran J Med Sci. 2016;41(4):305–313. EDN: XZAAMT
  54. Anwar M. The effect of melatonin on eye lens of rats exposed to ultraviolet radiation. Comp Biochem Physiol C Toxicol Pharmacol. 2001;129(1): 57–63. doi: 10.1016/s1532-0456(01)00180-6
  55. Bardak Y, Özertürk Y, Özgüner F, et al. Effect of melatonin against oxidative stress in ultraviolet-B exposed rat lens. Curr Eye Res. 2000;20(3): 225–230. doi: 10.1076/0271-3683(200003)2031-9ft225
  56. Shirazi A, Haddadi GH, Asadi-Amoli F, et al. Radioprotective effect of melatonin in reducing oxidative stress in rat lenses. Cell J. 2011;13(2):79–82.
  57. Taysi S, Memisogullari R, Koc M, et al. Melatonin reduces oxidative stress in the rat lens due to radiation-induced oxidative injury. Int J Radiat Biol. 2008;84(10):803–808. doi: 10.1080/09553000802390932
  58. Karslioglu I, Ertekin MV, Taysi S, et al. Radioprotective effects of melatonin on radiation-induced cataract. J Radiat Res. 2005;46(2):277–282. doi: 10.1269/jrr.46.277
  59. Alkozi HA, Navarro G, Franco R, Pintor J. Melatonin and the control of intraocular pressure. Prog Retin Eye Res. 2020;75:100798. doi: 10.1016/j.preteyeres.2019.100798 EDN: NVSTNH
  60. Al-Qassab H, Cleeves LA, Francis PL, et al. Is there a central nervous withdrawal syndrome associated with discontinuing long-term treatment with propranolol? Hum Toxicol. 1988;7(3):249–254. doi: 10.1177/096032718800700303
  61. Ferraro S, Nuria de Zavalia, Belforte N, Amir S. In utero exposure to valproic-acid alters circadian organisation and clock-gene expression: implications for autism spectrum disorders. Front Behav Neurosci. 2021;15:711549. doi: 10.3389/fnbeh.2021.711549 EDN: DMDYHG
  62. Pintor J, Martin L, Pelaez T, et al. Involvement of melatonin MT3 receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol. 2001;416(3):251–254. doi: 10.1016/s0014-2999(01)00864-0 EDN: AMVSFX
  63. Li KL, Shan SW, Lin FY, et al. Regulation of aqueous humor secretion by melatonin in porcine ciliary epithelium. Int J Mol Sci. 2023;24(6):5789. doi: 10.3390/ijms24065789 EDN: JUNUFY
  64. Alkozi H, Sánchez-Naves J, de Lara MJ, et al. Elevated intraocular pressure increases melatonin levels in the aqueous humour. Acta Ophthalmol. 2017;95(3):e185–e189. doi: 10.1111/aos.13253
  65. Ma XP, Shen MY, Shen GL, et al. Melatonin concentrations in serum of primary glaucoma patients. Int J Ophthalmol. 2018;11(8):1337–1341. doi: 10.18240/ijo.2018.08.14 EDN: VJHEYU
  66. Aydin E, Sahin S. Increased melatonin levels in aqueous humor of patients with proliferative retinopathy in type 2 diabetes mellitus. Int J Ophthalmol. 2016;9(5):721–724. doi: 10.18240/ijo.2016.05.15
  67. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg. 2009;108(4):1146–1151. doi: 10.1213/ane.0b013e3181907ebe
  68. Crooke A, Huete-Toral F, Martínez-Águila A, et al. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. J Pharmacol Exp Ther. 2013;346(1): 138–145. doi: 10.1124/jpet.112.202036
  69. Martínez-Águila A, Fonseca B, Bergua A, Pintor J. Melatonin analogue agomelatine reduces rabbit’s intraocular pressure in normotensive and hypertensive conditions. Eur J Pharmacol. 2013;701(1–3):213–217. doi: 10.1016/j.ejphar.2012.12.009
  70. Martínez-Águila A, Fonseca B, Pérez de Lara MJ, Pintor J. Effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine on the intraocular pressure of normal and glaucomatous mice. J Pharmacol Exp Ther. 2016;357(2):293–299. doi: 10.1124/jpet.115.231456
  71. Alkozi HA, Pintor J. TRPV4 activation triggers the release of melatonin from human non-pigmented ciliary epithelial cells. Exp Eye Res. 2015;136:34–37. doi: 10.1016/j.exer.2015.04.019
  72. Pescosolido N, Gatto V, Stefanucci A, Rusciano D. Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients. Ophthalmic Physiol Opt. 2015;35(2):201–205. doi: 10.1111/opo.12189
  73. Lledó VE, Alkozi HA, Pintor J. Yellow filter effect on melatonin secretion in the eye: Role in IOP regulation. Curr Eye Res. 2019;44(6):614–618. doi: 10.1080/02713683.2019.1570276
  74. Sakanaka K, Kawazu K, Tomonari M, et al. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. Biol Pharm Bull. 2008;31(8):1590–1595. doi: 10.1248/bpb.31.1590
  75. Alarma-Estrany P, Crooke A, Peral A, Pintor J. Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Auton Neurosci. 2007;137(1–2):63–66. doi: 10.1016/j.autneu.2007.07.004
  76. Mizumoto K, Gosho M, Iwaki M, Zako M. Ocular parameters before and after steep Trendelenburg positioning for robotic-assisted laparoscopic radical prostatectomy. Clin Ophthalmol. 2017;11:1643–1650. doi: 10.2147/OPTH.S139874
  77. Serle JB, Wang RF, Peterson WM, et al. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma. 2004;13(5):385–388. doi: 10.1097/01.ijg.0000133150.44686.0b
  78. Pastor-Idoate S, Mateos-Olivares M, Sobas EM, et al. Short-wavelength light-blocking filters and oral melatonin administration in patients with retinitis pigmentosa: protocol for a randomized controlled trial. JMIR Res Protoc. 2023;12:e49196. doi: 10.2196/49196 EDN: FHFLJL
  79. Mitsui K, Saeki K, Tone N, et al. Short-wavelength light exposure at night and sleep disturbances accompanied by decreased melatonin secretion in real-life settings: a cross-sectional study of the HEIJO-KYO cohort. Sleep Med. 2022;90:192–198. doi: 10.1016/j.sleep.2022.01.023 EDN: EHDMGN
  80. Shabanov PD, Arushanyan EB, Bayramov AA, et al. Psychoneuroendocrinology2024: new trends in development. Shabanov PD, editor. Saint Petersburg: ArtExpress; 2025. 544 p. ISBN: 978-5-4391-1025-4 (In Russ.) EDN: AXGECL
  81. Arushanyan EB, Ovanesov KB. Peculiarities of psychotropic effect of melatonin depending on dose and time of the day. Pharmacology and Toxicology. 1989;52(6):33–37. EDN: SGKXHP
  82. Sarala N, Bhuvana K, Sangeetha T, Kanthamani K. Effect of preoperative melatonin on anxiety and pain in patient undergoing phacoemulsification cataract surgery. Oman J Ophthalmol. 2025;18(2):167–171. doi: 10.4103/ojo.ojo_217_23 EDN: XAHDEB
  83. Khezri MB, Merate H. The effects of melatonin on anxiety and pain scores of patients, intraocular pressure, and operating conditions during cataract surgery under topical anesthesia. Indian J Ophthalmol. 2013;61(7):319–324. doi: 10.4103/0301-4738.99637
  84. Khezri MB, Oladi MR, Atlasbaf A. Effect of melatonin and gabapentin on anxiety and pain associated with retrobulbar eye block for cataract surgery: A randomized double-blind study. Indian J Pharmacol. 2013;45(6):581–586. doi: 10.4103/0253-7613.121368
  85. Kanat C, Altun Uğraş G. Effects of abdominal massage on bowel activity and pulmonary function test results in older patients undergoing partial hip replacement: a randomized controlled trial. J Perianesth Nurs. 2025. doi: 10.1016/j.jopan.2025.07.016 EDN: GXTCXC
  86. Haddadi S, Shahrokhirad R, Ansar MM, et al. Efficacy of preoperative administration of acetaminophen and melatonin on retrobulbar block associated pain in cataract surgery. Anesth Pain Med. 2018;8(5):e61041. doi: 10.5812/aapm.61041

Copyright (c) 2026 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.